208 related articles for article (PubMed ID: 28043744)
1. Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer.
Freudenthal B; Williams GR
Clin Oncol (R Coll Radiol); 2017 May; 29(5):325-328. PubMed ID: 28043744
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
[TBL] [Abstract][Full Text] [Related]
3. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
4. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
5. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
6. Thyroid Hormone Suppression Therapy.
Biondi B; Cooper DS
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):227-237. PubMed ID: 30717904
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
8. Reduced insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH.
De Melo TG; Souza AL; Ficher E; Fernandes AM; Montali Da Assumpção LV; Monte Alegre S; Zantut-Wittmann DE
Endocr Res; 2018 May; 43(2):73-79. PubMed ID: 29083246
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
Ippolito S; Ippolito R; Peirce C; Esposito R; Arpaia D; Santoro C; Pontieri G; Cocozza S; Galderisi M; Biondi B
Thyroid; 2016 Nov; 26(11):1528-1534. PubMed ID: 27558484
[TBL] [Abstract][Full Text] [Related]
10. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
11. Thyroid-hormone therapy and thyroid cancer: a reassessment.
Biondi B; Filetti S; Schlumberger M
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):32-40. PubMed ID: 16929364
[TBL] [Abstract][Full Text] [Related]
12. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
13. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
14. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
[TBL] [Abstract][Full Text] [Related]
15. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C; Wémeau JL
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
[TBL] [Abstract][Full Text] [Related]
16. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
17. Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer.
Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Kim JH; Hur KY; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2017 Sep; 87(3):286-291. PubMed ID: 28375573
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy.
Gigliotti BJ; Jasim S
Endocrine; 2024 Feb; 83(2):251-258. PubMed ID: 37824045
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hormone therapy in differentiated thyroid cancer.
Grani G; Ramundo V; Verrienti A; Sponziello M; Durante C
Endocrine; 2019 Oct; 66(1):43-50. PubMed ID: 31617165
[TBL] [Abstract][Full Text] [Related]
20. Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer.
Lee JC; Song BS; Kang YM; Kim YR; Kang YE; Lee JH; Shong M; Yi HS
Front Endocrinol (Lausanne); 2021; 12():769074. PubMed ID: 34858341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
